Under the agreement, JHP Pharma will be responsible for manufacturing and supply of an approved therapy used in cancer patients.
JHP Pharma manufactures sterile injectables, biologics, vaccines, ophthalmics and otics for large and small pharmaceutical and biotech organizations.
JHP Pharma president and co-founder Stuart Hinchen said this will be the second multi-year contract JHP has entered during the last two months.
"These agreements are examples of how our approach to ongoing investment in our people and facilities allow us to focus on customer needs which results in rising, sustainable growth," Hinchen said.
"Our Rochester, Michigan manufacturing site has a solid history of successful partnerships, manufacturing both clinical and commercial products."